According to a Zacks analysis, both Pediatrix Medical Group (MD) and HealthEquity (HQY) hold a Zacks Rank of #2 (Buy), indicating improving earnings outlooks; however, MD appears to be the superior value option. MD's forward P/E ratio is 9.70 compared to HQY's 28.08, its PEG ratio is 1.02 versus HQY's 1.38, and its P/B ratio is 1.65 compared to HQY's 4.15, resulting in a Value grade of B for MD and C for HQY.
Both Pediatrix Medical Group (MD) and HealthEquity (HQY), operating within the Medical Services sector, currently hold a Zacks Rank of #2 (Buy), signifying an improving earnings outlook driven by positive analyst estimate revisions. However, a deeper dive into valuation metrics reveals a distinct difference: Pediatrix Medical Group exhibits more attractive value characteristics, with a forward P/E ratio of 9.70, a PEG ratio of 1.02, and a P/B ratio of 1.65. These figures contribute to MD's Zacks Value grade of B and a positive per-ticker sentiment score of 0.3. In contrast, HealthEquity presents a higher valuation profile, with a forward P/E of 28.08, a PEG ratio of 1.38, and a P/B ratio of 4.15, leading to a Zacks Value grade of C and a slightly negative per-ticker sentiment of -0.2. The comparative analysis concludes that, based on these traditional value metrics, Pediatrix Medical Group is positioned as the superior value option at this time, despite both companies having positive earnings outlooks.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
Positive
Sentiment Score
0.30
Ticker Sentiment
